DE19575026I2 - Tricyclische Verbindungen Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung - Google Patents

Tricyclische Verbindungen Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung

Info

Publication number
DE19575026I2
DE19575026I2 DE1995175026 DE19575026C DE19575026I2 DE 19575026 I2 DE19575026 I2 DE 19575026I2 DE 1995175026 DE1995175026 DE 1995175026 DE 19575026 C DE19575026 C DE 19575026C DE 19575026 I2 DE19575026 I2 DE 19575026I2
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
composition containing
preparation
tricyclic compounds
compounds process
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE1995175026
Other languages
German (de)
English (en)
Inventor
Masakuni Okuhara
Hirokazu Tanaka
Toshio Goto
Tohru Kino
Hiroshi Hatanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB848430455A external-priority patent/GB8430455D0/en
Priority claimed from GB858502869A external-priority patent/GB8502869D0/en
Priority claimed from GB858508420A external-priority patent/GB8508420D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE19575026I2 publication Critical patent/DE19575026I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • C12R2001/55—Streptomyces hygroscopicus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y10S435/898—Streptomyces hygroscopicus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE1995175026 1984-12-03 1985-11-30 Tricyclische Verbindungen Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung Active DE19575026I2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB848430455A GB8430455D0 (en) 1984-12-03 1984-12-03 Fr-900506 substance
GB858502869A GB8502869D0 (en) 1985-02-05 1985-02-05 Ws 7238 substances
GB858508420A GB8508420D0 (en) 1985-04-01 1985-04-01 Fr-900506 & fr-900525 substances

Publications (1)

Publication Number Publication Date
DE19575026I2 true DE19575026I2 (de) 2002-03-28

Family

ID=27262535

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1995175026 Active DE19575026I2 (de) 1984-12-03 1985-11-30 Tricyclische Verbindungen Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung
DE3587806T Expired - Lifetime DE3587806T2 (de) 1984-12-03 1985-11-30 Tricyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3587806T Expired - Lifetime DE3587806T2 (de) 1984-12-03 1985-11-30 Tricyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung.

Country Status (24)

Country Link
US (15) US4894366A (enExample)
EP (1) EP0184162B1 (enExample)
JP (6) JPH0720970B2 (enExample)
KR (5) KR930010704B1 (enExample)
CN (1) CN1013687B (enExample)
AT (1) ATE104984T1 (enExample)
AU (1) AU592067B2 (enExample)
CA (1) CA1338491C (enExample)
CY (1) CY1912A (enExample)
DE (2) DE19575026I2 (enExample)
DK (1) DK169550B1 (enExample)
ES (1) ES8705038A1 (enExample)
FI (2) FI87803C (enExample)
GR (1) GR852904B (enExample)
HK (1) HK18596A (enExample)
HU (1) HU195250B (enExample)
IE (1) IE62865B1 (enExample)
IL (2) IL92345A (enExample)
LU (1) LU90317I2 (enExample)
MX (1) MX9202943A (enExample)
NL (1) NL960023I2 (enExample)
NO (1) NO168372C (enExample)
NZ (1) NZ214407A (enExample)
PT (1) PT81589B (enExample)

Families Citing this family (317)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5266692A (en) * 1984-12-03 1993-11-30 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5254562A (en) * 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
ATE98700T1 (de) * 1987-06-05 1994-01-15 Fujisawa Pharmaceutical Co Anti-fr-900506-stoffe-antikoerper und hoechstempfindliches enzym-immunoassay-verfahren.
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
DE3844904C2 (de) * 1987-11-09 1997-01-30 Sandoz Ag Neue Verwendung von 11,28-Dioxa-4-azatricyclo-[22.3.1.0·4·,·9·]octacos-18-en-Derivaten
AT400808B (de) * 1987-11-09 1996-03-25 Sandoz Ag Verwendung von tricyclischen verbindungen zur herstellung von topischen arzneimitteln
DE3838035C2 (de) * 1987-11-09 1994-03-24 Sandoz Ag Neue Verwendung von 11,28-dioxa-4-azatricyclo[22.3.1.O·4··,··9·]octacos-18-en-Derivaten
PH26083A (en) * 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
US5366971A (en) * 1987-11-09 1994-11-22 Sandoz Ltd. Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them
ES2071681T3 (es) * 1987-12-09 1995-07-01 Fisons Plc Compuestos macrociclicos.
GB8728820D0 (en) * 1987-12-09 1988-01-27 Fisons Plc Compounds
AT407957B (de) * 1987-12-17 2001-07-25 Novartis Erfind Verwalt Gmbh Neue verwendung von 11,28-dioxa-4-azatricyclo- (22.3.1.04,9)octacos-18-en-derivaten und sie enthaltende pharmazeutische zubereitungen
EP0323865A1 (en) * 1988-01-07 1989-07-12 Merck & Co. Inc. Novel immunosuppressant agent
US4981792A (en) * 1988-06-29 1991-01-01 Merck & Co., Inc. Immunosuppressant compound
US5290772A (en) * 1988-06-29 1994-03-01 Merck & Co., Inc. Immunosuppressant agent
DE68921934T2 (de) * 1988-06-29 1995-10-19 Merck & Co Inc Immunsuppressives Agens.
DE68925080T2 (de) * 1988-08-01 1996-05-15 Fujisawa Pharmaceutical Co FR-901154- und FR-901155-Derivate, Verfahren zu ihrer Herstellung
US5202258A (en) * 1988-08-05 1993-04-13 Merck & Co., Inc. Immunosuppressant-producing culture
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
EP0358508A3 (en) * 1988-09-08 1991-03-20 Merck & Co. Inc. Novel immunosuppressant compound
CA1316916C (en) * 1988-10-12 1993-04-27 David Askin Hydroxide mediated fk-506 rearrangement product
US4980466A (en) * 1988-10-12 1990-12-25 Merck & Co., Inc. Hydroxide mediated FK-506 rearrangement product
EP0364031B1 (en) * 1988-10-12 1992-12-23 Merck & Co. Inc. Hydroxide mediated fk-506 rearrangement process
BE1003436A3 (fr) * 1988-11-29 1992-03-24 Sandoz Sa Derives cycliques et leurs metabolites, leur preparation et leur utilisation comme medicaments.
US4975372A (en) * 1989-01-13 1990-12-04 Merck & Co., Inc. Microbial transformation product of L-683,590
EP0378320A3 (en) * 1989-01-13 1990-11-28 Merck & Co. Inc. Microbial transformation product
EP0378317A3 (en) * 1989-01-13 1990-11-28 Merck & Co. Inc. Microbial transformation product of l-679,934
US5268370A (en) * 1989-01-13 1993-12-07 Merck & Co., Inc. Microbial transformation product of L-679,934
EP0388153B1 (en) * 1989-03-15 1994-12-28 Merck & Co. Inc. Immunosuppressant agent
US5272068A (en) * 1989-03-15 1993-12-21 Merck & Co., Inc. Process for producing immunosuppressant agent L-683942 by fermentation
DE69013189T2 (de) * 1989-03-15 1995-05-11 Merck & Co Inc Verfahren zur Herstellung einer immunosuppressiven Substanz (demethimmunomycin) durch Verwendung eines Stamm-Mutanten eines Mikroorganismus.
US4940797A (en) * 1989-03-23 1990-07-10 Merck & Co., Inc. Process for synthesis of FK-506 C10-C18 intermediates
US5155228A (en) * 1989-03-23 1992-10-13 Merck & Co., Inc. FK-506 C10-C18 process intermediates
US5057608A (en) * 1989-04-21 1991-10-15 Merck & Co., Inc. Immunoregulants, immunosuppressants, process to make ring expanded macrolide related to FK-506/FK-520
US5068323A (en) * 1989-04-21 1991-11-26 Merck & Co., Inc. Thermally re-arranged FK-506 derivatives having immunosuppressant activity
CA2014841A1 (en) * 1989-04-21 1990-10-21 Byron H. Arison Macrolides having immunosuppressive activity
US5270187A (en) * 1989-05-05 1993-12-14 Merck & Co., Inc. Microbial transformation product
US4987139A (en) * 1989-05-05 1991-01-22 Merck & Co., Inc. FK-520 microbial transformation product
EP0396400A1 (en) * 1989-05-05 1990-11-07 Merck & Co. Inc. Microbial transformation product
IE64214B1 (en) * 1989-06-06 1995-07-26 Fujisawa Pharmaceutical Co Macrolides for the treatment of reversible obstructive airways diseases
US5138052A (en) * 1989-06-13 1992-08-11 Merck & Co., Inc. L-683,590 microbial transformation product
CA2018710A1 (en) * 1989-06-13 1990-12-13 Shieh-Shung T. Chen L-683,590 microbial transformation product
EP0402931A1 (en) * 1989-06-14 1990-12-19 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
US5164525A (en) * 1989-06-30 1992-11-17 Merck & Co., Inc. Synthetic process for fk-506 type macrolide intermediates
US5235066A (en) * 1989-06-30 1993-08-10 Merck & Co., Inc. FK-506 type macrolide intermediate
EP0413532A3 (en) * 1989-08-18 1991-05-15 Fisons Plc Macrocyclic compounds
AU6286690A (en) * 1989-08-18 1991-04-03 Fisons Plc Macrocyclic compounds
US5011943A (en) * 1989-08-28 1991-04-30 Merck Frosst Canada, Inc. FK-506 C10 -C24 process intermediates
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc ΝέαÎđ ÎžÎąÎšÏÎŋΚυΚÎŧÎđΚιÎŊ ÎĩÎ―ÏŽÏƒÎĩÎđς ΚιÎđ Î―Î­Îą Ξέ?ÎŋÎīÎŋς χρÎŪσÎĩως τÎŋυς.
US5215995A (en) * 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
DE69021833T2 (de) * 1989-11-09 1996-03-21 Sandoz Ag Heteroatome enthaltende tricyclische Verbindungen.
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
IE904050A1 (en) * 1989-11-13 1991-05-22 Merck & Co Inc Aminomacrolides and derivatives having immunosuppressiveÂđactivity
GB8925797D0 (en) * 1989-11-15 1990-01-04 Fisons Plc Compositions
EP0444829A3 (en) * 1990-02-27 1992-06-03 Fisons Plc Immunosuppressive compounds
US5064835A (en) * 1990-03-01 1991-11-12 Merck & Co., Inc. Hydroxymacrolide derivatives having immunosuppressive activity
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
JPH05504956A (ja) * 1990-03-12 1993-07-29 č—ĪæēĒč–Žå“å·ĨæĨ­æ ŠåžäžšįĪū トナシã‚Ŋロ化合į‰Đ
WO1991013889A1 (en) * 1990-03-13 1991-09-19 Fisons Plc Immunosuppressive macrocyclic compounds
US5296489A (en) * 1990-03-13 1994-03-22 Fisons Immunosuppressive macrocyclic compounds
EP0455427A1 (en) * 1990-04-30 1991-11-06 Merck & Co. Inc. Deoxymacrolide derivatives having immunosuppressive activity
WO1991017754A1 (en) * 1990-05-11 1991-11-28 Fujisawa Pharmaceutical Co., Ltd. Methods for treating and preventing inflammation of mucosa and blood vessels using fk 506 and related compounds
JPH05507915A (ja) * 1990-06-11 1993-11-11 č—ĪæēĒč–Žå“å·ĨæĨ­æ ŠåžäžšįĪū į‰đį™šæ€§čĄ€å°æŋæļ›å°‘性įīŦ斑į—…およãģバã‚ŧドã‚Ķį—…æēŧį™‚č–ŽčĢ―造ãŪためãŪï―†ï―‹ïž•ïžïž–į­‰ãŪマã‚ŊロãƒĐã‚Īド化合į‰ĐãŪį”Ļ途
US5643901A (en) * 1990-06-11 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating idiopathic thrombocytopenic purpura
US5210030A (en) * 1990-06-25 1993-05-11 Merck & Co., Inc. Process for selectively acylating immunomycin
US5190950A (en) * 1990-06-25 1993-03-02 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
CA2044846A1 (en) * 1990-06-25 1991-12-26 Thomas R. Beattie Antagonists of immunosuppressive macrolides
US5342935A (en) * 1990-06-25 1994-08-30 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
GB9014136D0 (en) * 1990-06-25 1990-08-15 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
GB9014681D0 (en) * 1990-07-02 1990-08-22 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
MY110418A (en) * 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
EP0466365A3 (en) * 1990-07-03 1992-04-15 Merck & Co. Inc. Novel immunosuppressant fermentation products of a microorganism
GB2245891A (en) * 1990-07-09 1992-01-15 Fujisawa Pharmaceutical Co Tricyclo compounds
GB2246350A (en) * 1990-07-23 1992-01-29 Fujisawa Pharmaceutical Co Tricyclo compounds
US5089517A (en) * 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
WO1992003441A1 (en) * 1990-08-18 1992-03-05 Fisons Plc Macrocyclic compounds
GB2247620A (en) * 1990-09-07 1992-03-11 Fujisawa Pharmaceutical Co The use of macrolide compounds for cytomegalovirus infection
CA2051872A1 (en) * 1990-09-24 1992-03-25 Kevin M. Byrne Directed biosynthesis process for prolyl-immunomycin
GB2248184A (en) * 1990-09-28 1992-04-01 Fujisawa Pharmaceutical Co New use of macrolide compounds for active oxygen-mediated diseases
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5348966A (en) * 1990-10-24 1994-09-20 Fujisawa Pharmaceutical Co., Ltd. Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds
CA2054128A1 (en) * 1990-10-29 1992-04-30 Kevin M. Byrne Process for the production of analogues of immunomycin
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
GB2249787A (en) * 1990-11-19 1992-05-20 Fujisawa Pharmaceutical Co Lactone compounds
GB9027471D0 (en) * 1990-12-19 1991-02-06 Fujisawa Pharmaceutical Co Novel compound
US5194378A (en) * 1991-01-28 1993-03-16 Merck & Co., Inc. Process for producing fk-506
US5116756A (en) * 1991-01-28 1992-05-26 Merck & Co., Inc. Process for producing FK-506
WO1992013862A1 (en) * 1991-02-05 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Lactone compounds
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
ATE198708T1 (de) * 1991-04-26 2001-02-15 Fujisawa Pharmaceutical Co Verwendung von makrolid-verbindungen gegen augenerkrankungen
US5262533A (en) * 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5250678A (en) * 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
EP0528452A1 (en) * 1991-06-19 1993-02-24 Merck & Co. Inc. Immunomycin enzymatic and/or microbial methylation products
US5225403A (en) * 1991-06-25 1993-07-06 Merck & Co., Inc. C-21 hydroxylated FK-506 antagonist
US5273979A (en) * 1991-08-01 1993-12-28 Merck & Co., Inc. C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5198358A (en) * 1991-08-28 1993-03-30 Merck & Co., Inc. Microorganism for producing C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5149701A (en) * 1991-08-01 1992-09-22 Merck & Co., Inc. C-31 methylated FR-900520 cyclic hemiketal immunosuppressant agents
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
KR100351222B1 (ko) * 1991-09-05 2002-09-05 ė•„ëģīíŠļ 럮ëģī럮터ëĶŽėĶˆ ë§Ī큮로ė‚ŽėīíīëĶ­ ëĐīė—­ ėĄ°ė ˆė œ 및 ėīė˜ ė œėĄ°ë°Đëē•
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
ZA926812B (en) 1991-09-09 1993-04-28 Merck & Co Inc O-heteroaryl,o-alkylheteroaryl,o-alkenylheteroaryl and o-alkynylheteroaryl macrolides having immunosupressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5164495A (en) * 1991-09-18 1992-11-17 Abbott Laboratories Method for preparing a dicarboxylic acid half-acid ester of FK506
US5221625A (en) * 1992-01-10 1993-06-22 Merck & Co., Inc. Cyclcic FR-900520 microbial biotransformation agent
WO1993014780A1 (en) * 1992-01-28 1993-08-05 Abraham Karpas The use of a compound for the manufacture of a medicament for the treatment of hiv infection
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ãƒ•ã‚Ąã‚Īã‚ķマčĢ―č–Žæ ŠåžäžšįĪū 新čĶãŠåĪ§į’°įŠķãƒĐã‚ŊトãƒģおよãģそãŪį”Ÿį”Ģ菌
US5612316A (en) * 1992-03-02 1997-03-18 Pfizer Inc. Fluorosugar derivatives of macrolides
FI944014A7 (fi) * 1992-03-02 1994-09-01 Pfizer Makrolidien desosaminojohdannaiset immuunivastetta heikentÃĪvinÃĪ ainein a ja sieniÃĪ vastustavina aineina
EP0629209B1 (en) * 1992-03-02 1997-05-14 Pfizer Inc. Sugar derivatives of macrolides
ATE159725T1 (de) * 1992-03-02 1997-11-15 Pfizer 2-aminozuckermakrolid-derivate
ES2089723T3 (es) 1992-03-27 1996-10-01 American Home Prod 29-demetoxirapamicina para inducir la inmunodepresion.
CA2091194A1 (en) * 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
HUT66531A (en) * 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
AU4400593A (en) * 1992-06-05 1994-01-04 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5284840A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5264355A (en) * 1992-07-02 1993-11-23 Merck & Co., Inc. Methlating enzyme from streptomyces MA6858
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5324644A (en) * 1992-07-28 1994-06-28 Merck & Co., Inc. Process for producing immunosuppressant agent
DE69331585T2 (de) * 1992-08-12 2002-08-08 Fujisawa Pharmaceutical Co., Ltd. Monoklonaler antikÃķrper spezifisch fÞr das fk-506-bindende protein, methode zur bestimmung des gehaltes an fk-506-bindendem protein in einer probe und reagenzsatz dafÞr
US5365948A (en) * 1992-08-21 1994-11-22 J & W Mcmichael Software Inc. Method for use in treating a patient with FK 506 to prevent an adverse immune response
US5290689A (en) * 1992-09-28 1994-03-01 Merck & Co., Inc. New cyclic FR-900520 microbial biotransformation agent
US5268281A (en) * 1992-09-28 1993-12-07 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5283183A (en) * 1992-09-28 1994-02-01 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5268282A (en) * 1992-09-28 1993-12-07 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5318895A (en) * 1992-10-05 1994-06-07 Merck & Co., Inc. Aspergillus niger mutants
GB9227055D0 (en) * 1992-12-29 1993-02-24 Fujisawa Pharmaceutical Co New use
DE4300478C2 (de) * 1993-01-11 1998-05-20 Eos Electro Optical Syst Verfahren und Vorrichtung zum Herstellen eines dreidimensionalen Objekts
JPH08507788A (ja) * 1993-03-17 1996-08-20 ã‚ĒボツトãƒŧãƒĐボãƒĐトナマ゚ į―Ūæ›č„‚į’°åžã‚ĒミãƒģåŦ有åĪ§į’°įŠķ免į–ŦčŠŋįŊ€å‰Ī
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
GB2279006A (en) * 1993-06-03 1994-12-21 Fujisawa Pharmaceutical Co Treatment of amyotrophic lateral sclerosis
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ロマショãƒģå‰Ī
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5359060A (en) * 1993-07-06 1994-10-25 Pfizer, Inc. Phosponated derivatives of macrolides
CA2166892A1 (en) * 1993-07-30 1995-02-09 Yat Sun Or Activated macrolactams having immunomodulatory activities
GB2281294A (en) * 1993-08-23 1995-03-01 Fujisawa Pharmaceutical Co Process for producing half esters of the macrolide FK506
US5616588A (en) 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
UA41884C2 (uk) * 1993-11-05 2001-10-15 АОÐĩŅ€Ņ–ÐšÐ°Ð― ÐĨÐūŅƒÐž ПŅ€ÐūÐīаКŅ‚Ņ КÐūŅ€ÐŋÐūŅ€ÐĩÐđŅˆÐ― ÐĄÐŋÐūŅŅ–Ðą ÐēŅ–ÐīÐūКŅ€ÐĩОÐŧÐĩÐ―Ð―Ņ Ņ€Ð°ÐŋаОŅ–Ņ†ÐļÐ―Ņƒ ÐēŅ–Ðī КÐļŅÐŧÐūŅ‚Ð―ÐļŅ…, ÐūŅÐ―ÐūÐēÐ―ÐļŅ… Ņ‚а Ð―ÐĩÐŋÐūÐŧŅŅ€Ð―ÐļŅ… Ð―ÐĩÐđŅ‚Ņ€Ð°ÐŧŅŒÐ―ÐļŅ… ÐīÐūОŅ–ŅˆÐūК, ÐŋŅ€ÐļŅŅƒŅ‚Ð―Ņ–Ņ… Ðē КÐūÐ―Ņ†ÐĩÐ―Ņ‚Ņ€Ð°Ņ‚Ņ– ÐĩКŅŅ‚Ņ€Ð°ÐšŅ‚Ņ–Ðē Ņ„ÐĩŅ€ÐžÐĩÐ―Ņ‚аŅ†Ņ–ÐđÐ―ÐūÐģÐū ÐąŅƒÐŧŅŒÐđÐūÐ―Ņƒ Ð°ÐąÐū ОаŅ‚ÐūŅ‡Ð―ÐļŅ… Ņ€ÐūзŅ‡ÐļÐ―Ņ–Ðē
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
US5880280A (en) * 1994-06-15 1999-03-09 Merck & Co., Inc. Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive activity
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
EP0786986B1 (en) 1994-10-26 2002-03-20 Novartis AG Use of an unsaturated fatty alcohol
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
WO2000066106A2 (en) * 1999-04-30 2000-11-09 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
US5616595A (en) * 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
DE69630798T2 (de) 1995-09-19 2004-09-23 Fujisawa Pharmaceutical Co., Ltd. Aerosolzusammensetzungen
NZ333657A (en) 1996-07-30 2000-05-26 Novartis Ag A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin
KR100244164B1 (ko) * 1997-07-15 2000-03-02 ęđ€ėšĐė˜Ĩ ėˆ˜ėšĐė„ą ęģ ëķ„ėž-타큮로ëĶŽëŽīėŠĪ ė ‘í•Đėēī 화í•Đ뎞 및 ę·ļė˜ ė œėĄ° ë°Đëē•
US6562620B2 (en) * 1997-09-19 2003-05-13 Mcgill University Medium to promote islet cell survival
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US20030129215A1 (en) 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7357942B2 (en) 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US8257726B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US8257725B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US8394398B2 (en) 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US8057816B2 (en) 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
EP1056454B1 (en) * 1998-02-23 2003-05-02 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for treating glaucoma
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
AU749623B2 (en) 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
RU2203058C2 (ru) * 1998-04-27 2003-04-27 ÐĪŅƒÐīзÐļŅÐ°Ðēа ÐĪаŅ€ÐžÐ°ŅŅŒŅŽŅ‚ÐļКаÐŧ КÐū., ЛŅ‚Ðī. ÐĪаŅ€ÐžÐ°Ņ†ÐĩÐēŅ‚ÐļŅ‡ÐĩŅÐšÐ°Ņ КÐūОÐŋÐūзÐļŅ†ÐļŅ
PL345598A1 (en) 1998-07-17 2001-12-17 Agouron Pharma Compounds, compositions, and methods for stimulating neuronal growth and elongation
US7455853B2 (en) 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
CA2343880C (en) 1998-10-02 2008-08-26 Kosan Biosciences, Inc. Polyketide synthase enzymes and recombinant dna constructs therefor
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
JP2002540211A (ja) * 1999-03-31 2002-11-26 ã‚ĒボットãƒŧãƒĐボãƒĐトナマ゚ フã‚Đã‚đフェマトåŦ有åĪ§į’°å…į–ŦčŠŋįŊ€č–Ž
US6121257A (en) * 1999-03-31 2000-09-19 Abbott Laboratories Sulfamate containing macrocyclic immunomodulators
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US7018405B2 (en) 2000-12-22 2006-03-28 Avantec Vascular Corporation Intravascular delivery of methylprednisolone
US7083642B2 (en) 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US6939375B2 (en) 2000-12-22 2005-09-06 Avantac Vascular Corporation Apparatus and methods for controlled substance delivery from implanted prostheses
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
US6656460B2 (en) 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
US7452692B2 (en) * 2002-02-13 2008-11-18 Teva GyÃģgyszergyÃĄr ZÃĄrtkÃķrÞen MÞkÃķdÃķ RÃĐszvÃĐnytÃĄrsasÃĄg Method for extracting a macrolide from biomatter
WO2003068980A2 (en) 2002-02-13 2003-08-21 Biogal Gyogyszergyar Rt Method for extracting a macrolide from biomatter
EP1478327B1 (en) * 2002-02-22 2015-04-29 Meda AB Method of reducing and treating uvb-induced immunosuppression
WO2004003214A1 (en) * 2002-06-28 2004-01-08 Biocon Limited Solid state fermentation and fed batch for the production of an immunosuppressant
EP1536850B1 (en) 2002-09-06 2016-08-10 Abbott Laboratories Medical device having hydration inhibitor
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
AU2003209664A1 (en) * 2003-02-10 2004-08-30 Biocon Limited Solid state fermentation and fed batch for the production of an immunosuppressant
US20060169199A1 (en) * 2003-03-31 2006-08-03 Vilmos Keri Crystallization and purification of macrolides
TW200504079A (en) 2003-03-31 2005-02-01 Biogal Gyogyszergyar Crystallization and purification of macrolides
US20060177500A1 (en) * 2003-07-09 2006-08-10 Hee-Jong Shin Solid dispersion of tacrolimus
DE602004010059T2 (de) * 2003-07-24 2008-09-11 Teva Gyogyszergyar ZartkÃķruen MukÃķdo Reszvenytarsasag Verfahren zur aufreinigung von makroliden
KR20060052722A (ko) * 2003-08-05 2006-05-19 가ëķ€ė‹œí‚Ī가ėīėƒĪ 가ë„Īėđī ėƒėēīėœ ėđ˜ėšĐ ėŠĪ텐íŠļ
CN1859909B (zh) 2003-08-29 2011-04-06 į”Ÿå‘―å‘Ļ期čŊį‰Đå…Žåļ åŦ有äŧ–å…‹čŽŦåļįš„囚态分æ•Ģä―“
BRPI0414000B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composiçÃĢo farmacÊutica sÃģlida oral de liberaçÃĢo prolongada contendo tacrolimus na forma de uma dispersÃĢo sÃģlida, forma de dosagem, e, uso da composiçÃĢo farmacÊutica
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2005038009A2 (en) * 2003-10-17 2005-04-28 Ranbaxy Laboratories Limited Production of tacrolimus (fk-506) using new streptomyces species
EP1689390B1 (en) 2003-11-21 2011-02-09 Zalicus Inc. Methods and reagents for the treatment of inflammatory disorders
EP1697383B1 (en) * 2003-12-05 2014-04-23 Biocon Limited Process for the purification of tacrolimus
KR100485877B1 (ko) * 2003-12-30 2005-04-28 ėĒ…ę·žë‹đ바ėīė˜Ī ėĢžė‹íšŒė‚Ž 타큮ëĄĪëĶŽëŽīėŠĪëĨž ėƒė‚°í•˜ëŠ” ëŊļėƒëŽž 및 ėīëĨž ėīėšĐ한타큮ëĄĪëĶŽëŽīėŠĪė˜ 대량 ėƒė‚°ë°Đëē•
US20050176080A1 (en) * 2004-02-10 2005-08-11 Vani Bodepudi Hapten, immunogens and derivatives of ascomycin useful for preparation of antibodies and immunoassays
JP4949227B2 (ja) 2004-03-19 2012-06-06 ã‚ĒボットãƒŧãƒĐボãƒĐトナマ゚ バãƒŦマãƒģおよãģプロテマゞからãŪåĪšå‰Ī送達
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
CA2562805C (en) 2004-04-12 2014-03-11 Biocon Limited Process for the production of macrolides using a novel strain, streptomyces sp. bicc 7522
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
JP2006014722A (ja) * 2004-06-02 2006-01-19 Keio Gijuku 遚䞝子ママã‚Ŧマ及ãģそãŪåˆĐį”Ļ
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
EP1768692B8 (en) * 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
JP2008512126A (ja) * 2004-09-10 2008-04-24 ã‚Ēã‚Īバッã‚Ŋã‚đ ãƒ•ã‚Ąãƒžãƒžã‚·ãƒĨマテã‚Ģã‚ŦãƒŦã‚š ã‚đポノツノã‚đト ã‚Ļã‚đ ãƒŦチェニム ã‚ŠãƒĄã‚žãƒ‹ãƒ  įĩæ™ķčģŠã‚ŋã‚Ŋロナムã‚đãŪ単é›Ēæģ•
CN101031654A (zh) * 2004-09-10 2007-09-05 侊į“Ķ克æ–ŊåˆķčŊ有限兎åļ įŧ“æ™ķäŧ–å…‹čŽŦåļįš„分įĶŧæ–đæģ•
GT200500282A (es) * 2004-10-12 2006-05-04 Heteroatomos conteniendo compuestos triciclicos.
ITMI20042098A1 (it) * 2004-11-03 2005-02-03 Antibioticos Spa Processo per la purificazione di tacrolimus
EP1817314A1 (en) 2004-12-01 2007-08-15 Teva GyÃģgyszergyÃĄr ZÃĄrtkÃķruen MukÃķdo RÃĐszvenytarsasÃĄg Non-hygroscopic and powdery amorphous pimecrolimus
JP2008524239A (ja) * 2004-12-15 2008-07-10 ã‚ĻãƒĐãƒģ ãƒ•ã‚Ąãƒžãƒž ã‚Īãƒģã‚ŋマナショナãƒŦ ナミテã‚Ģド ナノįē’子ãŪã‚ŋã‚Ŋロナムã‚đčĢ―å‰Ī
JP2007523201A (ja) * 2004-12-22 2007-08-16 テバ ã‚ļョã‚ļã‚ŧãƒŦã‚ļãƒĢマãƒŦ ã‚ķâˆ’ãƒˆã‚ąãƒŦã‚Ļãƒģ ãƒ ã‚ąãƒ‰ ノ−ã‚đベニãƒĨã‚ŋ−ãƒŦシãƒĢシãƒĢ−グ ã‚ŋã‚Ŋロナムã‚đをįēūčĢ―するæ–đæģ•
WO2006074358A1 (en) * 2005-01-03 2006-07-13 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
MX2007006119A (es) * 2005-01-05 2007-07-19 Teva Gyogyszergyar Zartkoruen Tacrolimus amorfo y preparacion de el.
ATE532064T1 (de) * 2005-01-13 2011-11-15 Univ Keio Genmarker und dessen verwendung
WO2006102359A2 (en) 2005-03-23 2006-09-28 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
WO2007032777A2 (en) 2005-03-23 2007-03-22 Abbott Laboratories Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
WO2007053193A2 (en) 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
CN1876822B (zh) * 2005-06-06 2010-05-12 äļŠæĩ·åļ‚农čŊį ”įĐķ所 äŧ–å…‹čŽŦåļįš„䚧į”ŸčŒæ ŠåŠį”Ÿäš§æ–đæģ•
WO2007013017A1 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited A process for purification of macrolides
ITMI20051549A1 (it) * 2005-08-05 2007-02-06 Antibioticos Spa Purificazione del tacrolimus su supporti dimorigine vegetale
WO2007029082A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited An improved fermentation process for preparing ascomycin
US20080318289A1 (en) * 2005-10-05 2008-12-25 Parveen Kumar Fermentation Processes for the Preparation of Tacrolimus
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
AU2006308655B2 (en) 2005-11-01 2010-09-23 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
TWI435729B (zh) 2005-11-09 2014-05-01 Combinatorx Inc æēŧį™‚į—…į—‡äđ‹æ–đæģ•ïžŒįĩ„合į‰Đ及åĨ—įĩ„
US7678901B2 (en) 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
US7622477B2 (en) 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
TW200815458A (en) * 2006-03-15 2008-04-01 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for purifying Tacrolimus
US8022188B2 (en) * 2006-04-24 2011-09-20 Abbott Laboratories Immunosuppressant binding antibodies and methods of obtaining and using same
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
CA2659549C (en) 2006-06-09 2013-07-30 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
EP2457589A1 (en) 2006-08-31 2012-05-30 Astellas Pharma Inc. Reverse targeting lipid vesicle
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
US20090082386A1 (en) * 2006-11-06 2009-03-26 Erzsebet Meszarosne Sos Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
CA3027598C (en) 2007-01-10 2020-07-21 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008109347A2 (en) * 2007-03-02 2008-09-12 Yale University Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
CA2783589A1 (en) 2007-03-09 2008-09-18 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
PL2167033T4 (pl) 2007-05-30 2018-08-31 Veloxis Pharmaceuticals A/S Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
KR100891313B1 (ko) 2007-08-17 2009-03-31 (ėĢž) ė œë…ļ텍 ë‹īėēī로 ėž‘ėšĐ하는 흡ė°Đė„ą ėˆ˜ė§€ė˜ ė œęģĩė— ė˜í•œ íŠļëĶŽė‚Žėīíī로화í•Đ뎞ė˜ ėƒė‚° 및 ėķ”ėķœ ë°Đëē•
ES2614498T3 (es) 2007-09-14 2017-05-31 The Regents Of The University Of Michigan Inhibidores de ATPasa F1F0 y mÃĐtodos relacionados
UA99839C2 (ru) 2007-11-06 2012-10-10 ДзÐĩ РÐļÐīÐķÐĩÐ―Ņ‚Ņ ОŅ„ ДзÐĩ ÐŪÐ―ÐļÐēÐĩŅ€ŅÐļŅ‚Ðļ ОŅ„ МÐļŅ‡ÐļÐģÐ°Ð― БÐĩÐ―Ð·ÐūÐīÐļазÐĩÐŋÐļÐ―ÐūÐ―ÐūÐēŅ‹Ðĩ ŅÐūÐĩÐīÐļÐ―ÐĩÐ―ÐļŅ, ÐŋŅ€ÐļОÐĩÐ―ŅÐĩОŅ‹Ðĩ ÐŋŅ€Ðļ ÐŧÐĩŅ‡ÐĩÐ―ÐļÐļ КÐūÐķÐ―Ņ‹Ņ… ŅÐūŅŅ‚ÐūŅÐ―ÐļÐđ
US8921642B2 (en) * 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
KR101003042B1 (ko) 2008-03-17 2010-12-21 ėĒ…ę·žë‹đ바ėīė˜Ī ėĢžė‹íšŒė‚Ž ęģ ėˆœë„ 타큮로ëĶŽëŽīėŠĪė˜ ė •ė œ ë°Đëē•
WO2009126623A2 (en) * 2008-04-08 2009-10-15 Amyris Biotechnologies, Inc. Expression of heterologous sequences
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
JP5567573B2 (ja) 2008-09-11 2014-08-06 ã‚ķ ナマã‚ļェãƒģツ りブ ã‚ķ ãƒĶニバマシテã‚Ģ りブ ミシゎãƒģ ã‚ĒナマãƒŦグã‚Ēニã‚ļãƒģï―†ïž‘ï―†ïžâˆ’ï―ï―”ï―ã‚Ēマゞé˜ŧåŪģå‰ĪおよãģそれãĻé–Ēé€Ģするæ–đæģ•
KR100910165B1 (ko) 2008-09-18 2009-07-30 (ėĢž) ė œë…ļ텍 ė€ ėīė˜Ļ ėšĐė•Ą ėķ”ėķœė„ ėīėšĐ한 ëķˆíŽí™” ė•Œí‚Žęļ°ëĨž 가ė§„ ë―í†Ī 화í•Đ뎞 ė •ė œë°Đëē•
US8575189B2 (en) * 2008-10-08 2013-11-05 Takata Seiyaku Co., Ltd. Tacrolimus preparation for external applications
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
CN101712686B (zh) * 2009-06-22 2012-08-29 éēå—åˆķčŊ集å›Ē股äŧ―有限兎åļ äļ€į§å‘é…ĩæķēäļ­äŧ–å…‹čŽŦåļįš„分įĶŧįšŊ化æ–đæģ•
EP2272963A1 (en) * 2009-07-09 2011-01-12 LEK Pharmaceuticals d.d. Process for Preparation of Tacrolimus
EP2470020A4 (en) 2009-09-18 2013-03-13 Univ Michigan BENZODIAZEPINONE COMPOUNDS AND TREATMENT METHODS THEREWITH
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
JP5856064B2 (ja) 2009-11-17 2016-02-09 ã‚ķ ナマã‚ļェãƒģツ りブ ã‚ķ ãƒĶニバマシテã‚Ģ りブ ミシゎãƒģ æēŧį™‚į‰đ性を有する−ベãƒģã‚ūã‚ļã‚Ēゞピãƒģ−−ã‚ļã‚Šãƒģおよãģé–Ēé€Ģ化合į‰Đ
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
US8951595B2 (en) 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
US8480620B2 (en) 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
WO2011100975A2 (en) 2010-02-17 2011-08-25 Lifecycle Pharma A/S Stabilized tacrolimus composition
JP2013527145A (ja) 2010-03-31 2013-06-27 ã‚Ūナマドãƒŧãƒ•ã‚Ąãƒžãƒžã‚ŧットãƒŧã‚ĻãƒŦã‚ĻãƒŦシマ ナãƒģåŦ有æīŧ性化å‰ĪãŪįŦ‹ä―“éļ択įš„合成
WO2011163600A2 (en) 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration
KR101261131B1 (ko) 2010-08-24 2013-05-06 ėī화ė—ŽėžëŒ€í•™ęĩ ė‚°í•™í˜‘ë Ĩë‹Ļ ė‹ ę·œ 타큮ëĄĪëĶŽëŽīėŠĪ ėœ ë„ėēī, ėƒęļ° ėœ ë„ėēīëĨž 폎í•Ļ하는 ė‹ ęē― ëģīí˜ļėšĐ ėĄ°ė„ąëŽž, ėƒęļ° ėœ ë„ėēīëĨž 폎í•Ļ하는 ëĐīė—­ ė–ĩė œėšĐ ėĄ°ė„ąëŽž, ėƒęļ° ėœ ë„ėēīė˜ ėƒė‚° ë°Đëē• 및 ėƒęļ° ėœ ë„ėēīė˜ ėƒė‚° ę· ėĢž
MA34586B1 (fr) 2010-08-25 2013-10-02 Medis Lab Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees
US10117411B2 (en) 2010-10-06 2018-11-06 Dow Agrosciences Llc Maize cytoplasmic male sterility (CMS) C-type restorer RF4 gene, molecular markers and their use
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek ÃĐs alkalmazÃĄsaik
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
UA116648C2 (uk) 2013-03-14 2018-04-25 АÐŧКÐĩŅ€ÐžÐĩŅ ÐĪаŅ€ÐžÐ° АÐđÐĩŅ€ÐŧÐĩÐ―Ðī ЛŅ–ОŅ–Ņ‚ÐĩÐī ÐĪŅƒÐžÐ°Ņ€Ð°Ņ‚Ðļ ŅÐš ÐŋŅ€ÐūÐŧŅ–КÐļ Ņ‚а Ņ—Ņ… заŅŅ‚ÐūŅŅƒÐēÐ°Ð―Ð―Ņ ÐŋŅ€Ðļ ÐŧŅ–КŅƒÐēÐ°Ð―Ð―Ņ– Ņ€Ņ–Ð·Ð―ÐļŅ… заŅ…ÐēÐūŅ€ŅŽÐēÐ°Ð―ŅŒ
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
EP3760223A1 (en) 2013-04-03 2021-01-06 N-Fold Llc Nanoparticle composition for desensitizing a subject to peanut allergens
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
CN104650112B (zh) * 2013-11-18 2018-07-31 åąąäļœæ–°æ—ķäŧĢčŊäļšæœ‰é™å…Žåļ äŧ–å…‹čŽŦåļ8-äļ™åŸšįąŧäžžį‰Đįš„åˆķåĪ‡æ–đæģ•
UY35927A (es) 2013-12-31 2015-07-31 Dow Agrosciences Llc ?gen restaurador rf3 de tipo s de la esterilidad masculina citoplasmÃĄtica del maíz (cms), marcadores moleculares y sus usos?.
EP3094324A4 (en) * 2014-01-13 2017-02-22 Amplyx Pharmaceuticals, Inc. Antifungal compounds
EP3094314B1 (en) 2014-01-16 2021-06-23 MUSC Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
KR101694879B1 (ko) * 2014-08-01 2017-01-12 ėĢžė‹íšŒė‚Ž ėļíŠļ론바ėīė˜Ī테큮놀로ė§€ ëĐīė—­ė–ĩė œí™œė„ą ė—†ėī ė‹ ęē―ėžŽėƒí™œė„ąėī ėœ ė§€ë˜ëŠ” fk506 ėœ ë„ėēī 및 ę·ļė˜ ėšĐ도
EP3246036B1 (en) 2014-10-28 2021-10-13 Koushi Yamaguchi Medicine for improving pregnancy-induced hypertension syndrome
AU2016308568A1 (en) 2015-08-19 2018-02-22 Vivus Llc Pharmaceutical formulations
EP3307322B1 (en) 2015-09-04 2021-02-17 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
CN106074367A (zh) * 2016-07-20 2016-11-09 äļ­åąąåĪ§å­Ķäļ­åąąįœžį§‘äļ­åŋƒ åŦfk506įąŧ化合į‰Đ/fkbp蛋į™―äšŒčšä―“įš„čŊį‰Đįŧ„合į‰Đ及å…ķåˆķåĪ‡æ–đæģ•
CN108384819B (zh) * 2017-02-03 2021-06-25 äļŠæĩ·åŒŧčŊå·Ĩäļšį ”įĐķé™Ē äļ€į§į”Ļ䚎发é…ĩäŧ–å…‹čŽŦåļįš„åŸđå…ŧ埚äŧĨ及发é…ĩæ–đæģ•
RU2686779C1 (ru) * 2018-07-26 2019-04-30 ÐžÐąŅ‰ÐĩŅŅ‚ÐēÐū Ņ ÐūÐģŅ€Ð°Ð―ÐļŅ‡ÐĩÐ―Ð―ÐūÐđ ÐūŅ‚ÐēÐĩŅ‚ŅŅ‚ÐēÐĩÐ―Ð―ÐūŅŅ‚ŅŒŅŽ "ИзÐēаŅ€ÐļÐ―Ðū ÐĪаŅ€ÐžÐ°" ÐĻŅ‚аОО streptomyces tsukubensis - ÐŋŅ€ÐūÐīŅƒŅ†ÐĩÐ―Ņ‚ Ņ‚аКŅ€ÐūÐŧÐļОŅƒŅÐ° Ðļ ŅÐŋÐūŅÐūÐą ÐŋÐūÐŧŅƒŅ‡ÐĩÐ―ÐļŅ Ņ‚аКŅ€ÐūÐŧÐļОŅƒŅÐ°
US20210228551A1 (en) 2018-08-10 2021-07-29 Koushi Yamaguchi Therapeutic agent for humoral immunity-related diseases in maternofetal relationship
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
WO2020117134A1 (en) 2018-12-04 2020-06-11 Ä°lko Ä°laç SanayiĖ‡ Ve TiĖ‡caret A.Ş. Stable tacrolimus ointment formulation for topical treatment of skin conditions
JPWO2020129348A1 (ja) 2018-12-18 2021-11-04 晃åē åąąåĢ äļåĶŠãƒŧäļč‚ēį—‡ãūたãŊåĶŠåĻ įŠķ態をæ”đ善するためãŪ薮å‰Ī
WO2020163594A1 (en) * 2019-02-07 2020-08-13 The Regents Of The University Of California Immunophilin binding agents and uses thereof
GR1009790B (el) 2019-03-20 2020-08-03 ÎĶÎąÏÎžÎąÏ„ÎĩÎ― Α.Β.Ε.Ε. ÎĢΚÎĩÏ…ÎąÏƒÎžÎą Ï€ÎąÏÎąÏ„ÎĩÏ„ÎąÎžÎĩÎ―Î·Ï‚ ÎąÏ€ÎŋÎīÎĩσΞÎĩυσης πÎŋυ πÎĩρÎđÎŧιΞÎēÎąÎ―ÎĩÎđ Ï„ÎąÎšÏÎŋÎŧÎđΞÎŋυς
US20220296572A1 (en) 2021-03-03 2022-09-22 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3244592A (en) * 1962-06-09 1966-04-05 Arai Tadashi Ascomycin and process for its production
JPS54110000A (en) * 1978-02-17 1979-08-29 Kaken Pharmaceut Co Ltd Novel streptovaricin c derivative
US4309504A (en) * 1980-01-28 1982-01-05 Eli Lilly And Company Process for preparing narasin
US4654334A (en) * 1980-10-08 1987-03-31 International Minerals & Chemical Corp. Manganese-containing antibiotic agents
US4390546A (en) * 1981-12-07 1983-06-28 Merck & Co., Inc. Antiparasitic macrolide from a strain of Streptomyces hygroscopicus
US4415669A (en) * 1981-12-07 1983-11-15 Merck & Co., Inc. Substance and process for its production
US4510317A (en) * 1983-07-28 1985-04-09 Hoffmann-La Roche Inc. Antibiotic X-14934A
GB8430455D0 (en) * 1984-12-03 1985-01-09 Fujisawa Pharmaceutical Co Fr-900506 substance
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5266692A (en) * 1984-12-03 1993-11-30 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5254562A (en) * 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
PH26083A (en) * 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
US5956352A (en) * 1992-04-24 1999-09-21 Digital Equipment Corporation Adjustable filter for error detecting and correcting system

Also Published As

Publication number Publication date
EP0184162B1 (en) 1994-04-27
US5830717A (en) 1998-11-03
KR930010707B1 (ko) 1993-11-08
DE3587806T2 (de) 1994-08-25
IE62865B1 (en) 1995-03-08
MX9202943A (es) 1992-06-30
US4929611A (en) 1990-05-29
JPH0346445B2 (enExample) 1991-07-16
NO168372C (no) 1992-02-12
LU90317I2 (fr) 1999-01-11
JPH0372483A (ja) 1991-03-27
FI87803B (fi) 1992-11-13
JPH11343294A (ja) 1999-12-14
US5624842A (en) 1997-04-29
US6482845B1 (en) 2002-11-19
KR930010705B1 (ko) 1993-11-08
AU5059685A (en) 1986-06-12
CN1013687B (zh) 1991-08-28
IE852971L (en) 1986-06-03
CY1912A (en) 1985-11-30
ATE104984T1 (de) 1994-05-15
US4894366A (en) 1990-01-16
FI854731A0 (fi) 1985-11-29
IL92345A (en) 1991-06-10
PT81589B (pt) 1987-10-20
EP0184162A3 (en) 1989-02-08
US20030170831A1 (en) 2003-09-11
US20030229115A1 (en) 2003-12-11
JP2746134B2 (ja) 1998-04-28
JPH0720970B2 (ja) 1995-03-08
JP2976966B2 (ja) 1999-11-10
JP3211891B2 (ja) 2001-09-25
KR930010706B1 (ko) 1993-11-08
FI864527A0 (fi) 1986-11-07
FI85977B (fi) 1992-03-13
CA1338491C (en) 1996-07-30
NO168372B (no) 1991-11-04
HK18596A (en) 1996-02-09
ES8705038A1 (es) 1987-04-16
FI854731L (fi) 1986-06-04
NL960023I1 (nl) 1996-12-02
GR852904B (enExample) 1986-04-01
US4956352A (en) 1990-09-11
IL77222A (en) 1991-06-10
FI864527L (fi) 1986-11-07
US6028097A (en) 2000-02-22
ES549478A0 (es) 1987-04-16
PT81589A (en) 1986-01-01
FI85977C (fi) 1992-06-25
EP0184162A2 (en) 1986-06-11
US6201005B1 (en) 2001-03-13
US20050124646A1 (en) 2005-06-09
JPH1112281A (ja) 1999-01-19
US5565559A (en) 1996-10-15
NO854833L (no) 1986-06-04
US20040029908A1 (en) 2004-02-12
JPH0372484A (ja) 1991-03-27
FI87803C (fi) 1993-02-25
DK556285D0 (da) 1985-11-29
HU195250B (en) 1988-04-28
KR930010708B1 (ko) 1993-11-08
AU592067B2 (en) 1990-01-04
CN85109492A (zh) 1986-06-10
JP2828091B2 (ja) 1998-11-25
NZ214407A (en) 1989-11-28
JPH07224066A (ja) 1995-08-22
US5496727A (en) 1996-03-05
HUT41842A (en) 1987-05-28
DK169550B1 (da) 1994-11-28
KR930010704B1 (ko) 1993-11-08
US5110811A (en) 1992-05-05
KR860004918A (ko) 1986-07-16
NL960023I2 (nl) 1997-06-02
JPH1067783A (ja) 1998-03-10
DK556285A (da) 1986-06-04
DE3587806D1 (de) 1994-06-01

Similar Documents

Publication Publication Date Title
DE19575026I2 (de) Tricyclische Verbindungen Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung
DE59208559D1 (de) Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE58534T1 (de) 2-pyrimidinyl-l-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE45153T1 (de) Benzisoselenazolthione, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische produkte.
ATE160344T1 (de) Heterozyklische alkylamine, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten
ATE324T1 (de) Hydroxypropyl-triazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
DE68925080D1 (de) FR-901154- und FR-901155-Derivate, Verfahren zu ihrer Herstellung
DE69429570D1 (de) Galanthamin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
ATE70184T1 (de) Pharmazeutische zusammensetzung zur heilung und verhuetung kardiovaskularer krankheiten und verfahren zu ihrer herstellung.
ATE42553T1 (de) Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
ATE18226T1 (de) Pyrrolo(2,3-d)carbazolderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung.
ATE200492T1 (de) 7-acyl-3-(substituierte carbamoyloxy) cephem verbindungen, verfahren zu ihrer herstellung und anwendung
DE58909594D1 (de) 6-Oxo-pyridazinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
ATE42291T1 (de) Spiro(indolo(1,7-ab>(1,5>benzodiazepin-2,4'piperidine> und zwischenprodukte, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel.
DE3887626D1 (de) 2-Oxa-isocephem-Verbindungen, diese enthaltende Zusammensetzungen und Verfahren zu deren Herstellung.
ATE25517T1 (de) Delta-1-pyrrolin-thiolactimaether und verfahren zu ihrer herstellung.
ATE275576T1 (de) UngesÃĪttigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
ATE5318T1 (de) 4-niedrig-hydrocarbyl-3-phenoxypyridin-1-oxide, verfahren zu ihrer herstellung, diese verbindungen enthaltende zusammensetzungen und ihre verwendung.
ATE38837T1 (de) Gesaettigten stickstoff enthaltende tricyclische dione, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
ATA52288A (de) Malonsaeurederivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzung, enthaltend diese verbindungen
ATE44024T1 (de) Verbindungen mit antihyperlipaemischer aktivitaet, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.